I agree that this site is using cookies. You can find further informations here.
X
Bias, Peter
47  results:
Search for persons X
?
1

The Path Towards a Tailored Clinical Biosimilar Development:

Schiestl, Martin ; Ranganna, Gopinath ; Watson, Keith...
BioDrugs.  34 (2020)  3 - p. 297-306 , 2020
Link: https://doi.org/10.1007/..
 
?
2

A pharmacokinetic study of lipegfilgrastim in children with..:

Belogurova, Margarita B. ; Kizyma, Zoryana P. ; Garami, Miklós...
Cancer Chemotherapy and Pharmacology.  79 (2016)  1 - p. 155-164 , 2016
Link: https://doi.org/10.1007/..
 
?
3

Efficacy and safety of lipegfilgrastim compared with placeb..:

Volovat, Constantin ; Bondarenko, Igor ; Gladkov, Oleg...
Supportive Care in Cancer.  24 (2016)  12 - p. 4913-4920 , 2016
Link: https://doi.org/10.1007/..
 
?
4

Randomized, active-controlled, comparative phase 3 efficacy..:

Strowitzki, Thomas ; Kuczynski, Waldemar ; Mueller, Arnd.
Reproductive Biology and Endocrinology.  14 (2016)  1 - p. , 2016
Link: https://doi.org/10.1186/..
 
?
5

Comment on "Biosimilar FSH preparations- are they identical..:

Strowitzki, Thomas ; Kuczynski, Waldemar ; Mueller, Arnd.
Reproductive Biology and Endocrinology.  14 (2016)  1 - p. , 2016
Link: https://doi.org/10.1186/..
 
?
6

Safety and efficacy of Ovaleap® (recombinant human follicle..:

Strowitzki, Thomas ; Kuczynski, Waldemar ; Mueller, Arnd.
Reproductive Biology and Endocrinology.  14 (2016)  1 - p. , 2016
Link: https://doi.org/10.1186/..
 
?
7

Cardiovascular Morbidity and Pure Red Cell Aplasia Associat..:

Lammerich, Andreas ; Balcke, Peter ; Bias, Peter..
Clinical Therapeutics.  38 (2016)  2 - p. 276-287.e4 , 2016
Link: https://doi.org/10.1016/..
 
?
8

Clinical safety of tbo-filgrastim, a short-acting human gra..:

Pettengell, Ruth ; Bias, Peter ; Mueller, Udo.
Supportive Care in Cancer.  24 (2016)  6 - p. 2677-2684 , 2016
Link: https://doi.org/10.1007/..
 
?
9

Phase 1 safety, tolerability, and pharmacokinetic study of ..:

Lammerich, Andreas ; Bias, Peter ; Gertz, Beate
International Journal of Women's Health.  , 2015
Link: https://doi.org/10.2147/..
 
?
10

Chemotherapy-associated treatment burden in breast cancer p..:

Gladkov, Oleg A. ; Buchner, Anton ; Bias, Peter..
Supportive Care in Cancer.  24 (2015)  1 - p. 395-400 , 2015
Link: https://doi.org/10.1007/..
 
?
11

Phase I, two-way, crossover study to demonstrate bioequival..:

Lammerich, Andreas ; Mueller, Arnd ; Bias, Peter
Reproductive Biology and Endocrinology.  13 (2015)  1 - p. , 2015
Link: https://doi.org/10.1186/..
 
?
12

Phase II dose-finding study of balugrastim in breast cancer..:

Gladkov, Oleg ; Moiseyenko, Vladimir ; Bondarenko, Igor N....
Medical Oncology.  32 (2015)  6 - p. , 2015
Link: https://doi.org/10.1007/..
 
?
13

Phase III, randomized, double-blind, placebo-controlled, mu..:

Volovat, Constantin ; Bondarenko, Igor M ; Gladkov, Oleg A...
SpringerPlus.  4 (2015)  1 - p. , 2015
Link: https://doi.org/10.1186/..
 
?
14

A randomized, double-blind, active control, multicenter, do..:

Buchner, Anton ; Elsässer, Reiner ; Bias, Peter
Breast Cancer Research and Treatment.  148 (2014)  1 - p. 107-116 , 2014
Link: https://doi.org/10.1007/..
 
?
15

Efficacy and Safety of Balugrastim Compared With Pegfilgras..:

Volovat, Constantin ; Gladkov, Oleg A. ; Bondarenko, Igor M....
Clinical Breast Cancer.  14 (2014)  2 - p. 101-108 , 2014
Link: https://doi.org/10.1016/..
 
1-15